Mirikizumab Demonstrates Superiority over Placebo in Phase 3 Maintenance Study in Ulcerative Colitis, Supporting Regulatory Submissions in 2022

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. CBRS
2. KBH
3. FDX
4. HONA
5. HTZ
6. HON
7. TTWO
8. HELP
9. GDYN
10. NKE

Go back to Mirikizumab Demonstrates Superiority over Placebo in Phase 3 Maintenance Study in Ulcerative Colitis, Supporting Regulatory Submissions in 2022
Lilly (Eli) & Co. (NYSE: LLY) Delayed: 1107.08 --0 (-0%)
Previous Close $1107.08    52 Week High $88.16 
Open $1107.08    52 Week Low $67.88 
Day High $1107.08    P/E 256.27 
Day Low $1107.08    EPS $4.32 
Volume 2,917